Sangamo Therapeutics chopping 120 jobs after Biogen, Novartis exit deals

The company's non-partnered programs will zero in on Fabry Disease gene therapy, a cell therapy for certain kidney transplant recipients and preclinical therapies targeting prions diseases and neurology.